Another study highlighting neutrophil-killing potential demonstrated that combination therapy involving tumor necrosis factor, CD40 agonist, and a tumor-binding antibody induced rapid mobilization and tumor infiltration of neutrophils [150]. The gene discussed is CD40; the disease is neoplasm.